Literature DB >> 28602606

Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data.

Max Carlos Ramírez-Soto1, Gutia Ortega-Cáceres2, César Cabezas3.   

Abstract

The first pilot vaccination program against hepatitis B in Peru was implemented in the hyperendemic Abancay province in 1991. To assess the impact of vaccination on mortality rates of hepatitis B-related hepatocellular carcinoma (HCC), cirrhosis, and fulminant hepatitis, we compared mortality trends before (1960-1990) and after (1991-2012) roll-out of the vaccination program, using death certificate data from the Municipalidad Provincial de Abancay. Our results showed that, following program roll-out, the overall mortality rates (per 100,000 population) decreased from 9.20 to 3.30 for HCC (95% CI, 1.28-10.48%; P<0.014), from 16.0 to 6.3 for cirrhosis (95% CI, 3.20-16.10%; P<0.004), and from 34.80 to 1.28 for fulminant hepatitis (95% CI, 16.70-50.30%; P<0.001). The absolute number of deaths attributable to cirrhosis (10 [8.80%] vs. 0.0%; P<0.001) and fulminant hepatitis (83 [40.0%] vs. 5 [19.20%]; P<0.026) decreased in 5-14-year-old children following vaccination. These findings showed reduced mortality rates of hepatitis B-related liver diseases, particularly cirrhosis and fulminant hepatitis in children under 15years, following implementation of the vaccination program against hepatitis B.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Fulminant hepatitis; Hepatitis B; Hepatocellular carcinoma; Peru; Vaccination against hepatitis B

Mesh:

Substances:

Year:  2017        PMID: 28602606     DOI: 10.1016/j.vaccine.2017.05.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

2.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

3.  Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology.

Authors:  Chimaobi M Anugwom; Manon Allaire; Sheikh Mohammad Fazle Akbar; Amir Sultan; Steven Bollipo; Angelo Z Mattos; Jose D Debes
Journal:  Hepatoma Res       Date:  2021-03-26

4.  Morbimortality Associated with Liver Cirrhosis in Peru: An Ecological Analysis for the Period of 2004-2016.

Authors:  Daniela Rojas-Acuña; Nilo Polo-Samillan; Angie Z Vasquez-Chavesta; Crist Escalante-Arias; Cristhian J Rios-Perez; Carlos J Toro-Huamanchumo
Journal:  Int J Environ Res Public Health       Date:  2022-07-25       Impact factor: 4.614

5.  Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.

Authors:  Cesar Cabezas; Omar Trujillo; Ángel Gonzales-Vivanco; Carlos Manuel Benites Villafane; Johanna Balbuena; Alfredo Oswaldo Borda-Olivas; Magna Aurora Suarez-Jara; Flor de María Peceros; Max Carlos Ramírez-Soto
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.